ES2515194T3 - Derivados de pirrolidina - Google Patents

Derivados de pirrolidina Download PDF

Info

Publication number
ES2515194T3
ES2515194T3 ES09718154.9T ES09718154T ES2515194T3 ES 2515194 T3 ES2515194 T3 ES 2515194T3 ES 09718154 T ES09718154 T ES 09718154T ES 2515194 T3 ES2515194 T3 ES 2515194T3
Authority
ES
Spain
Prior art keywords
alkyl
aryl
heteroaryl
independently
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09718154.9T
Other languages
English (en)
Inventor
Weir-Torn Jiaang
Yu-Sheng Chao
Ting-Yueh Tsai
Tsu Hsu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Health Research Institutes
Original Assignee
National Health Research Institutes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Health Research Institutes filed Critical National Health Research Institutes
Application granted granted Critical
Publication of ES2515194T3 publication Critical patent/ES2515194T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Abstract

Un compuesto de la siguiente fórmula:**Fórmula** donde cada uno de R1, R2, R3, R4, R5, y R6, independientemente, es H, halo, nitro, ciano, amino, hidroxi, alquilo, haloalquilo, alcoxi, ariloxi, aralquilo, ciclilo, heterociclilo, arilo, o heteroarilo; R7 es alquilo o heteroarilo, y R8 es H o alquilo; o R7 y R8, junto con el átomo de N al cual están unidos, forman un anillo monocíclico o bicíclico, saturado o insaturado, de 3-10 miembros opcionalmente sustituido con halo, CN, NO2, -OR', alquilo, arilo, heteroarilo, haloalquilo, hidroxialquilo, alcoxialquilo, -C(O)R', -SR', -S(O)R', - S(O)2R', -NR'R", -C(O)OR', -C(O)NR'R", -OC(O)R', -NR-C(O)R", -NR-C(O)OR", o -R'C(O)NR"R'"; siendo cada uno de R', R", y R'", independientemente, H, alquilo, o arilo; cada uno de m y n, independientemente, es 0, 1, 2, ó 3; y X es NRa, en el cual Ra es H, alquilo, o arilo.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9

Claims (1)

  1. imagen1
    imagen2
    imagen3
ES09718154.9T 2008-03-05 2009-02-25 Derivados de pirrolidina Active ES2515194T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3387708P 2008-03-05 2008-03-05
US33877 2008-03-05
PCT/US2009/035111 WO2009111239A2 (en) 2008-03-05 2009-02-25 Pyrrolidine derivatives

Publications (1)

Publication Number Publication Date
ES2515194T3 true ES2515194T3 (es) 2014-10-29

Family

ID=41054296

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09718154.9T Active ES2515194T3 (es) 2008-03-05 2009-02-25 Derivados de pirrolidina

Country Status (16)

Country Link
US (1) US8022096B2 (es)
EP (1) EP2252582B1 (es)
JP (1) JP5586484B2 (es)
KR (1) KR101634656B1 (es)
CN (1) CN101970402B (es)
AU (1) AU2009222198B2 (es)
BR (1) BRPI0906094B8 (es)
CA (1) CA2717518C (es)
ES (1) ES2515194T3 (es)
HK (1) HK1149261A1 (es)
MY (1) MY155630A (es)
NZ (1) NZ587911A (es)
RU (1) RU2494094C2 (es)
TW (1) TWI385163B (es)
WO (1) WO2009111239A2 (es)
ZA (1) ZA201006329B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
IN2015DN03795A (es) 2012-10-24 2015-10-02 Inserm Inst Nat De La Santé Et De La Rech Médicale
EP3116469B1 (en) 2014-03-10 2018-10-03 Mary Kay, Inc. Skin lightening compositions
CN104447478B (zh) * 2015-01-13 2016-04-13 佛山市赛维斯医药科技有限公司 一种含腈基金刚烷和酰胺结构的衍生物、其制备方法和用途
CN104496877B (zh) * 2015-01-13 2016-06-01 佛山市赛维斯医药科技有限公司 一种腈基金刚烷酰胺衍生物、其制备方法和用途
CN104478778B (zh) * 2015-01-13 2016-03-16 佛山市赛维斯医药科技有限公司 金刚烷酰胺类衍生物、其制备方法和用途
CN104447479B (zh) * 2015-01-13 2016-03-23 佛山市赛维斯医药科技有限公司 含金刚烷和酰胺类衍生物、其制备方法和用途
CN104529855B (zh) * 2015-01-13 2016-04-13 佛山市赛维斯医药科技有限公司 一种含羟基金刚烷和酰胺结构的衍生物、其制备方法和用途
US10426818B2 (en) 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes
WO2021136491A1 (zh) * 2019-12-31 2021-07-08 石药集团中奇制药技术（石家庄）有限公司 一种二肽基肽酶iv抑制剂的晶型及其制备方法和用途
CN114641277B (zh) * 2019-12-31 2023-06-13 石药集团中奇制药技术（石家庄）有限公司 一种二肽基肽酶4抑制剂的药物组合物及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2293651T3 (es) 1995-11-28 2008-03-16 Cephalon, Inc. Inhibidores de cisteina y serina proteasas derivados de aminoacidos d.
JP2000264882A (ja) * 1999-03-18 2000-09-26 Nippon Shokubai Co Ltd 有機アミド化合物およびその製造方法
GB9928330D0 (en) * 1999-11-30 2000-01-26 Ferring Bv Novel antidiabetic agents
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
US6861440B2 (en) 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
CN100430386C (zh) * 2002-11-07 2008-11-05 默克公司 苯丙氨酸衍生物作为二肽基肽酶抑制剂用于治疗或预防糖尿病
AU2003290577B2 (en) * 2002-11-07 2008-12-11 Merck Sharp & Dohme Corp. Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
JP2004203526A (ja) 2002-12-24 2004-07-22 Sharp Corp 記録装置
PT1595866T (pt) 2003-01-31 2016-09-14 Sanwa Kagaku Kenkyusho Co Cianopirrolidinas úteis para o tratamento entre outras de síndrome metabólica
JP2007511467A (ja) 2003-05-14 2007-05-10 タケダ サン ディエゴ インコーポレイテッド ジペプチジルペプチダーゼインヒビター
US20070093492A1 (en) 2004-03-09 2007-04-26 Weir-Torn Jiaang Pyrrolidine derivatives
CN1942186B (zh) * 2004-03-09 2010-10-06 国家卫生研究院 吡咯烷化合物
EP1760076A1 (en) * 2005-09-02 2007-03-07 Ferring B.V. FAP Inhibitors

Also Published As

Publication number Publication date
MY155630A (en) 2015-11-13
US8022096B2 (en) 2011-09-20
HK1149261A1 (en) 2011-09-30
AU2009222198B2 (en) 2014-05-08
EP2252582A2 (en) 2010-11-24
EP2252582B1 (en) 2014-07-23
RU2010140627A (ru) 2012-04-10
BRPI0906094B8 (pt) 2021-05-25
AU2009222198A1 (en) 2009-09-11
US20090227569A1 (en) 2009-09-10
CN101970402B (zh) 2013-12-18
BRPI0906094B1 (pt) 2019-11-12
CN101970402A (zh) 2011-02-09
KR20100129754A (ko) 2010-12-09
ZA201006329B (en) 2011-05-25
TWI385163B (zh) 2013-02-11
EP2252582A4 (en) 2012-03-07
JP5586484B2 (ja) 2014-09-10
WO2009111239A3 (en) 2009-10-29
NZ587911A (en) 2012-02-24
WO2009111239A2 (en) 2009-09-11
KR101634656B1 (ko) 2016-06-29
CA2717518A1 (en) 2009-09-11
BRPI0906094A2 (pt) 2016-07-05
TW200938530A (en) 2009-09-16
CA2717518C (en) 2017-03-21
JP2011513410A (ja) 2011-04-28
RU2494094C2 (ru) 2013-09-27

Similar Documents

Publication Publication Date Title
ES2515194T3 (es) Derivados de pirrolidina
AR064197A1 (es) Derivados de pirimidina y piridina inhibidores de la proteina quinasa
PE20130375A1 (es) Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos
AR076900A1 (es) Derivados heterociclicos nitrogenados utiles como agentes antivirales, composiciones farmaceuticas que los contienen y uso de los mismos como inhibidores del vhc
AR076171A1 (es) Pirazolopirimidinonas 1,6-disustituidas, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento del alzheimer, epilepsia y otras enfermedades del sistema nervioso central.
CY1119049T1 (el) Υποκατεστημενα πυρρολιδινο-2-καρβοξαμιδια
AR058885A1 (es) Compuestos de piperidina 3,5-sustituidos
AR052568A1 (es) Derivados de pirazolo -pirimidina como antagonstas de mglur2
ES2600636T3 (es) Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2
AR078976A1 (es) Inhibidores heterociclicos de la proteina ns5a codificada por el virus de la hepatitis c(vhc), composiciones farmaceuticas que los comprenden y uso de los mismos para tratar infecciones por vhc
CO6170406A2 (es) Derivados de 2-alquiltio-2-quinoliniloxi-acetamida como fungicidas
ECSP055974A (es) Síntesis de cloruros de 4 amino-2-butenoil y su uso en la preparación de 3-ciano quinolinas
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
AR098912A1 (es) Inhibidores de syk
CO6170361A2 (es) Composiciones y metodos para modular receptores de c-kit y pdgfr
AR055150A1 (es) Compuestos de isoindol - imido y composiciones que los comprenden y sus metodos de uso
ECSP12011684A (es) Inhibidores de los virus flaviviridae.
AR036093A1 (es) Compuestos derivados de tiazolidinilo, pirrolidinilo, oxazolidinilo, piperidilo, morfolinilo y tiomorfolinilo, su uso, composiciones farmaceuticas que los comprenden, y compuestos intermediarios
AR063420A1 (es) Derivados de 2-ciano-4-pirimidinil sustituidos,proceso de preparacion de los mismos,medicamentos que los contienen y su uso para el tratamiento de la malaria.
PE20140302A1 (es) Inhibidores del virus de la hepatitis c
AR080074A1 (es) Naftiridinas sustituidas y su uso como medicamentos
AR085489A1 (es) Derivados de triazolopiridinas, composiciones farmaceuticas que los contienen, proceso para prepararlos, intermediarios de dicho proceso y uso de los mismos para el tratamiento de enfermedades autoinmunes e inflamatorias
AR065927A1 (es) Derivados de 5,6-dihidro-1h-piridin-2-ona
AR077977A1 (es) Compuestos y composiciones como inhibidores de cinasa de proteina
AR069435A1 (es) Derivados de aminotiazol, proceso para la obtencion de los mismos, composiciones farmaceuticas y su uso como inhibidores de la fbpasa